Takeda Pharmaceutical (TAK) Accounts Payables: 2018-2025

  • Takeda Pharmaceutical's Accounts Payables fell 15.63% to $3.1 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $3.1 billion, marking a year-over-year decrease of 15.63%. This contributed to the annual value of $3.1 billion for FY2025, which is 17.77% down from last year.
  • Takeda Pharmaceutical's Accounts Payables amounted to $3.1 billion in Q1 2025, which was down 15.63% from $3.7 billion recorded in Q1 2024.
  • In the past 5 years, Takeda Pharmaceutical's Accounts Payables registered a high of $4.9 billion during Q1 2023, and its lowest value of $3.1 billion during Q1 2025.
  • Moreover, its 3-year median value for Accounts Payables was $3.7 billion (2024), whereas its average is $3.9 billion.
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 36.76% in 2022, then declined by 24.73% in 2024.
  • Quarterly analysis of 5 years shows Takeda Pharmaceutical's Accounts Payables stood at $3.2 billion in 2021, then spiked by 36.76% to $4.4 billion in 2022, then grew by 10.48% to $4.9 billion in 2023, then declined by 24.73% to $3.7 billion in 2024, then declined by 15.63% to $3.1 billion in 2025.
  • Its Accounts Payables was $3.1 billion in Q1 2025, compared to $3.7 billion in Q1 2024 and $4.9 billion in Q1 2023.